ORIGINAL ARTICLE |
|
Year : 2019 | Volume
: 26
| Issue : 4 | Page : 229-234 |
|
Real-world retrospective consecutive study of ab interno XEN 45 gel stent implant with mitomycin C in black and afro-latino patients with glaucoma: 40% required secondary glaucoma surgery at 1 year
Daniel Laroche1, Gideon Nkrumah2, Chester Ng2
1 Department of Ophthalmology, New York Eye and Ear of Mount Sinai, Icahn School of Medicine at Mount Sinai; Department of Ophthalmology, Advance Eyecare of New York, New York, NY, USA 2 Department of Ophthalmology, Advance Eyecare of New York, New York, NY, USA
Correspondence Address:
Dr. Daniel Laroche 49 West 127th Street, New York 10027, NY USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/meajo.MEAJO_126_19
|
|
PURPOSE: The aim of this study was to determine the postoperative course after the ab interno XEN45 Gel Stent implantation in Black and Afro-Latino, patients with glaucoma.
METHODS: This was a single-center, retrospective study. All patients with glaucoma who underwent ab interno XEN implantation were included in the study. All of the patients were Black and Afro-Latino making up the demographics of the local community. Investigated parameters were intraocular pressure (IOP), the number of medications, visual acuity, IOP-follow-up, intraoperative and postoperative complications, and additionally performed surgeries.
RESULTS: Of 20 eyes that had undergone the procedure with 1-year follow-up, eight failed before 12 months requiring additional glaucoma surgery. Of the 12 that were successful at 1 year, 9 (75%) eyes underwent XEN + cataract surgery and 3 (25%) had XEN surgery alone. Of the eyes that completed 12-month follow-up, the mean medicated IOP was 15.3 ± 6.2 mmHg at baseline, and 12.9 ± 4.5 mmHg at 12 months, a 16% IOP reduction. Mean medications dropped from 3.58 ± 0.7 preoperatively to 1.75 ± 1.5 at 12 months.
CONCLUSIONS: The ab interno XEN gel implant as a standalone procedure or combined with cataract surgery demonstrated a safe and sustained IOP reduction for only 60% of patients after 12 months. In Black and Afro-Latino patients receiving the ab interno XEN implant, 40% of patients needed additional surgery within 12 months.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|